Northside Capital Management LLC Buys New Stake in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Northside Capital Management LLC acquired a new stake in Zimmer Biomet Holdings, purchasing 57,362 shares valued at approximately $5.2 million during the second quarter.
• Analysts have issued positive ratings on Zimmer Biomet, with a consensus rating of "Moderate Buy" and an average price target of $113.16.
• Zimmer Biomet recently announced a quarterly dividend of $0.24 per share, which will be paid on October 31 and represents a 1.0% yield based on an annualized sum of $0.96.

Northside Capital Management LLC bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 57,362 shares of the medical equipment provider's stock, valued at approximately $5,232,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Garde Capital Inc. bought a new stake in Zimmer Biomet in the first quarter valued at about $29,000. Washington Trust Advisors Inc. bought a new stake in Zimmer Biomet during the first quarter worth about $30,000. Columbia River Financial Group LLC bought a new stake in Zimmer Biomet during the first quarter worth about $30,000. Menard Financial Group LLC bought a new stake in Zimmer Biomet during the fourth quarter worth about $30,000. Finally, Accent Capital Management LLC bought a new stake in Zimmer Biomet during the first quarter worth about $35,000. Institutional investors own 88.89% of the company's stock.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares in the company, valued at $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on ZBH shares. Rothschild Redb raised shares of Zimmer Biomet to a "strong-buy" rating in a research note on Thursday, September 18th. Redburn Partners set a $130.00 price objective on shares of Zimmer Biomet in a research note on Thursday, September 18th. UBS Group upped their price objective on shares of Zimmer Biomet from $91.00 to $96.00 and gave the stock a "sell" rating in a research note on Friday, August 8th. Stifel Nicolaus upped their target price on shares of Zimmer Biomet from $115.00 to $118.00 and gave the stock a "buy" rating in a research report on Friday, September 19th. Finally, Raymond James Financial upped their target price on shares of Zimmer Biomet from $104.00 to $113.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Zimmer Biomet presently has a consensus rating of "Moderate Buy" and an average price target of $113.16.

Zimmer Biomet Price Performance

Shares of ZBH stock opened at $100.29 on Wednesday. The firm's 50 day moving average is $100.35 and its 200-day moving average is $99.32. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $114.72. The firm has a market capitalization of $19.87 billion, a price-to-earnings ratio of 24.40, a PEG ratio of 2.34 and a beta of 0.68. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same period in the prior year, the business posted $2.01 earnings per share. Zimmer Biomet's revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet's dividend payout ratio is currently 23.36%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.